

Optimization and Evaluation of ^{177}Lu -Dotatoc as a Potential Agent for Peptide Receptor Radionuclide Therapy

Authors : H. Yousefnia, MS. Mousavi-Daramoroudi, S. Zolghadri, F. Abbasi-Davani

Abstract : High expression of somatostatin receptors on a wide range of human tumours makes them as potential targets for peptide receptor radionuclide tomography. A series of octreotide analogues were synthesized while [DOTA-DPhe1, Tyr3]octreotide (DOTATOC) indicated advantageous properties in tumour models. In this study, ^{177}Lu -DOTATOC was prepared with the radiochemical purity of higher than 99% in 30 min at the optimized condition. Biological behavior of the complex was studied after intravenous injection into the Syrian rats. Major difference uptake was observed compared to $^{177}\text{LuCl}_3$ solution especially in somatostatin receptor-positive tissues such as pancreas and adrenal.

Keywords : Biodistribution, ^{177}Lu , Octreotide, Syrian rats

Conference Title : ICRR 2015 : International Conference on Radiopharmacy and Radiopharmaceuticals

Conference Location : London, United Kingdom

Conference Dates : September 25-26, 2015